メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
近藤 征史
医学部・呼吸器内科学
h-index
7510
被引用数
43
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
1994 …
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(144)
類似のプロファイル
(6)
フィンガープリント
Masashi Kondoが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Pharmacology, Toxicology and Pharmaceutical Science
Lung Cancer
100%
Non Small Cell Lung Cancer
77%
Carboplatin
74%
Disease
50%
Chemotherapy
46%
Paclitaxel
46%
Fibrosing Alveolitis
42%
Pemetrexed
42%
Epidermal Growth Factor Receptor
42%
Docetaxel
37%
Coronavirinae
36%
SARS Coronavirus
30%
Clinical Trial
29%
Small Cell Lung Cancer
28%
Pleura Mesothelioma
28%
Placebo
26%
Overall Survival
25%
Creatinine
22%
Malignant Neoplasm
22%
Progression Free Survival
18%
Receptor
18%
Transforming Growth Factor
18%
Phase II Trials
16%
Osimertinib
16%
Brain Metastasis
16%
Rho Kinase
15%
Desensitization
15%
Initiation Factor 2
14%
Initiation Factor
14%
Favipiravir
14%
Transforming Growth Factor Beta
14%
Therapeutic Drug Monitoring
14%
Adrenergic Receptor
14%
Nintedanib
14%
Purinergic P2X Receptor
14%
Brigatinib
14%
Sarcoidosis
14%
Antibacterial Activity
14%
Midazolam
14%
Ventilator Induced Lung Injury
14%
Balofloxacin
14%
Anticoagulation Therapy
14%
Capsaicinoids
14%
Naldemedine
14%
Capsaicin
14%
Cyclic AMP
14%
Group Trial
14%
Interferon
14%
Cohort Study
14%
Lysophosphatidylcholine
14%
Keyphrases
Japanese Patients
47%
Brigatinib
42%
Previously Treated
42%
ALK-positive Lung Cancer
42%
Docetaxel
37%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
34%
Nab-paclitaxel
29%
Non-small Cell Lung Cancer (NSCLC)
29%
International Journals
28%
Pemetrexed
28%
Clinical Oncology
28%
Tyrosine Kinase Inhibitor
28%
Albumin Paclitaxel
28%
Malignant Pleural Mesothelioma
28%
Programmed Death-ligand 1 (PD-L1)
23%
Phase II Trial
17%
EIF2
14%
Lung Epithelial Cells
14%
Loss of Imprinting
14%
H19 Gene
14%
Idiopathic Pulmonary Fibrosis
14%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
14%
TAK1
14%
Gli1
14%
Plakoglobin
14%
Anchorage-independent Cell Growth
14%
P2X Receptors
14%
Extracellular Adenosine Triphosphate
14%
Echoic Features
14%
Transcriptional Regulation
14%
Bmal1
14%
Human Lung Fibroblasts
14%
Endobronchial Ultrasound
14%
Human Hepatocellular Carcinoma
14%
Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA)
14%
New Quinolone
14%
Mechanical Stretch
14%
Balofloxacin
14%
In Vitro Antibacterial Activity
14%
Renal Impairment
14%
Dosing Protocol
14%
Ventilator-induced Lung Injury
14%
Airway
14%
Resectable Lung Cancer
14%
FHIT Gene
14%
4-cycle
14%
Clinical Effect
14%
Oral Use
14%
Respiratory Infectious Diseases
14%
Confidence Interval
14%
Medicine and Dentistry
Non Small Cell Lung Cancer
76%
COVID-19
37%
Endobronchial Ultrasonography
28%
Transbronchial Biopsy
28%
Brigatinib
28%
Placebo
23%
Group Therapy
22%
Disease
20%
Lung Cancer
20%
Lung Cancer Cell Line
18%
Heterozygosity
17%
Programmed Cell Death
16%
Severe Acute Respiratory Syndrome Coronavirus 2
15%
Clinical Trial
15%
Favipiravir
14%
Cancer Cell
14%
Coronavirinae
14%
RNA
14%
Airway Smooth Muscle Cell
14%
Transbronchial Aspiration
14%
Adjuvant Chemotherapy
14%
Infectious Complication
14%
Microsatellite Instability
14%
Pulmonary Veno Occlusive Disease
14%
Tyrosine-Kinase Inhibitor
14%
Microtubule
14%
Cell Regeneration
14%
Thorax Radiography
14%
Pleura Plaque
14%
Anticoagulant Therapy
14%
Cohort Effect
14%
Staphylococcal Pneumonia
14%
Gemcitabine
14%
Endothelin 1
14%
Epidermal Growth Factor Receptor
14%
Mediastinal Lymphadenopathy
14%
Epithelial Cell Line
14%
Chromosome 12p
14%
Allele
14%
Clinical Oncology
14%
Tuberculous Peritonitis
14%
Treatment Effect
14%
Miliary Tuberculosis
14%
Carboplatin
14%
Anamorelin
14%
Breast Cancer
14%
Cachexia
14%
Naldemedine
14%
Pneumothorax
14%
Breathing Mechanics
14%
